Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Greater Concern than Hope about HTA: Mr Zulueta of PhRMA
May 14, 2012
- Interview with Alfonso G. Zulueta of PhRMA
May 14, 2012
- Participation in TPP to Lead to Higher NHI Prices: JMA VP Nakagawa
May 10, 2012
- 87% of Respondents Affirmative on Introduction of Medicoeconomic Assessment: JAPhMed Survey
May 9, 2012
- JPMA Compiles Manual for Providing Drugs in the Event of Disasters
April 24, 2012
- JPMA Opposes Haste Adoption of Cost-Effective HTA
April 20, 2012
- National Centers for Advanced and Specialized Medical Cares to Join NHO, JLHWO Hospitals in Joint Purchasing
April 20, 2012
- Degree of Drug Contribution Increased Most for HIV and AIDS: JHSF Survey
April 13, 2012
- MREAC Seeks to Contact 70 People Who Passed MR Exam through “Transitional Measure”
April 10, 2012
- CMRs Exceed 3000, Rapidly Increasing in Specialty Care: JCSOA
April 6, 2012
- 4 Specific Measures for Distribution Improvement: JPWA President Bessho
March 29, 2012
- JGA Announces GL for Disclosure of Payments to Medical Institutions by Member Companies
March 29, 2012
- JGA Announces Measures to Ensure Stable Supplies of Generic Drugs
March 27, 2012
- JGA to Start Providing Information in July on Out of Stock Generics
March 27, 2012
- NIBIO Offers Clinical Trial Information on Rare Diseases on Website
March 26, 2012
- Growth of Domestic Pharma Industry Will Require Individualized Strategies: FPMAJ Chairman Shoda
March 23, 2012
- IDMA President Doshi Expresses Hopes for Cooperation with Japanese Pharmaceutical Companies
March 21, 2012
- Drugstore Market Reaches ¥5.8 Trillion, 11 Straight Years of Growth: JACDS Survey
March 19, 2012
- Asia Partnership Conference Starts Talks for Early NDA Approval at Inauguration Meeting in Tokyo
March 19, 2012
- JMA “Totally Opposed” to Japan’s Participation in TPP
March 16, 2012
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…